The NIMML Institute (@NIMMLab) header
The NIMML Institute (@NIMMLab) profile picture

Tackling unsolved challenges in complex human #diseases with unmet clinical needs using #PrecisionMedicine #AI #Immunometabolism

Blacksburg, VA
Joined December 2013
Photo by The NIMML Institute (@NIMMLab)Photo by The NIMML Institute (@NIMMLab)Photo by The NIMML Institute (@NIMMLab)Photo by The NIMML Institute (@NIMMLab)Photo by The NIMML Institute (@NIMMLab)Photo by The NIMML Institute (@NIMMLab)Photo by The NIMML Institute (@NIMMLab)Photo by The NIMML Institute (@NIMMLab)Photo by The NIMML Institute (@NIMMLab)Photo by The NIMML Institute (@NIMMLab)
NIMML has published new research revealing immunometabolic drivers of GI ARS, including gene expression patterns linked to mortality and GI injury. Insights support developing new countermeasures for radiation exposure. Learn more businesswire.com/news/home/2… #PrecisionMedicine
57
On #WorldMSDay, we join the global MS community in raising awareness for why continued research matters. At #IMMUNOLOGY2026, we presented new data on the next wave of oral once-daily small molecules, showing immunoregulatory & neuroprotective signals across multiple MS models.
39
At #IMMUNOLOGY2026 we shared new data on omilancor, an oral, once-daily gut-restricted LANCL2 medicine—showing strong efficacy signals in IBD, recurrent C. difficile infection model and concomitant CDI and IBD. Read the article below.
At #IMMUNOLOGY2026 we shared new data on omilancor, an oral, once-daily gut-restricted LANCL2 medicine—showing strong efficacy signals in IBD, recurrent C. difficile infection model and concomitant CDI and IBD. Read the article: nimmunebio.com/nimmune-bioph…
110
At #IMMUNOLOGY2026, we presented new data showing that LANCL2 medicines reduced respiratory disease, lung lesions and inflammation and increased lung Tregs in mouse models of asthma. Read our recent article to learn more: linkedin.com/pulse/new-data-…
1
1
80
Proud to share that @NImmuneBio will present new data on LANCL2 medicines at #IMMUNOLOGY2026, highlighting novel immunometabolic approaches with pipeline‑in‑a‑drug potential across inflammatory, autoimmune and neurodegenerative diseases. Read more: businesswire.com/news/home/2…
1
91
The NIMML Institute retweeted
Dr. Josep Bassaganya‑Riera is launching a clinical program advancing NIM‑1324 a next‑gen oral, once-daily LANCL2 therapeutic for IBD. NIM‑1324 targets both gut and extraintestinal disease through a systemic approach. Results will be presented at #DDW2026. businesswire.com/news/home/2…
1
1
66
The NIMML Institute retweeted
Dr. Josep Bassaganya-Riera, our Founder & CEO, was featured on the Biotech Blueprint podcast, delving into the scientific underpinnings of how NImmune’s lead candidates outperform current IBD drugs in efficacy and safety. Listen here: open.spotify.com/show/6bn77q…
1
45
The NIMML Institute retweeted
Listen to Dr. Josep Bassaganya-Riera, Founder & CEO of NImmune, on @BiotechnologyPa’s Biotech Insiders podcast as he shares how AI is transforming drug development and why high-precision immunology is key to disrupting the I&I disease treatment paradigm. podcasts.apple.com/us/podcas…
1
1
42
The NIMML Institute retweeted
ICYMI: Eli Lilly and Nvidia recently announced a new partnership to leverage AI capabilities for drug discovery & development. At NImmune, we've successfully demonstrated how advanced AI models can greatly accelerate therapeutic discovery & development. nimmunebio.com/the-nimml-ins…
1
1
40
We are excited to contribute to the 3rd edition of “Goals in Nutrition Science” (2025–2030), a forthcoming initiative from @FrontNutrition sharing global perspectives on the future of the field, incl. a section on immunometabolism from our founder Josep Bassaganya-Riera. (1/2)
2
1
1
32
(2/2) At the NIMML Institute, our work studying immunometabolism continues to advance the science of how nutritional signals impact immune regulation and chronic disease. #NutritionScience #Immunometabolism #PrecisionHealth #Immunology #AutoimmuneDiseases #ImmunologyResearch
1
26
The NIMML Institute retweeted
Listen to Dr. Josep Bassaganya-Riera, Founder & CEO of NImmune, on the Honestquo VC Podcast as he discusses pioneering tech in precision medicine and shares insights from his journey as a biotech founder. Listen here: podcasts.apple.com/gh/podcas… #Biopharma #AI #PrecisionMedicine
1
1
79
The NIMML Institute retweeted
Listen to our Founder & CEO, Dr. Josep Bassaganya-Riera, on the @BioWorld Insider podcast, where he discusses how NImmune is leveraging the TITAN-X AI platform to advance precision medicine in inflammatory and autoimmune diseases. Listen here: bioworld.com/media/podcasts/…
2
3
190
The NIMML Institute retweeted
Today on #WorldIBDDay, we stand with the global IBD community in the fight against Crohn’s disease and ulcerative colitis. At NImmune, our team is advancing omilancor, a first-in-class oral therapeutic targeting LANCL2, now in Phase 3.
2
3
166
New data presented at #DDW2025 shows LANCL2 activation via omilancor outperforms anti-TL1A in IBD. Backed by our TITAN-X A.I. platform, results show superior efficacy, unmatched safety, and reversal of Treg/mitochondrial dysfunction in UC. Read more: businesswire.com/news/home/2…
1
4
115
The NIMML Institute retweeted
Thrilled to share that our Founder & CEO, Dr. Josep Bassaganya-Riera, was featured on @LaunchBio’s NextGen VC podcast to discuss his journey building Landos Biopharma from new scientific findings to a $600M market cap company. Listen here: launchbio.org/nextgen-vc-pod…
2
3
65
Excited to share new case studies in @AnnualReviews showing how our TITAN-X #AI platform fuels next-gen #immunology & #inflammation therapies. By unlocking novel targets like LANCL2, we’re advancing #PrecisionMedicine. Read the peer-reviewed article here: annualreviews.org/content/jo…
1
1
2
121
The NIMML Institute retweeted
Check out our Founder & CEO, Dr. Josep Bassaganya-Riera, on the Life Science & Biotech CEO Stories podcast as he shares his success story and how he's leading the charge in applying A.I. to biotech innovation. Listen here: biotechinsights.net/post/he-…
2
2
55
New editorial from Dr. Bassaganya-Riera introducing recent research on the use of computational modeling to study T-cell response. The power of advanced computational modeling of T-cell responses using the TITAN-X A.I. platform has accelerated target discovery & drug development.
Our Founder and CEO, Dr. Bassaganya-Riera, recently edited a collection of articles for @FrontiersIn Immunology on new computational modeling methods to study alloimmune T-cell responses. Read the full editorial here: frontiersin.org/journals/imm… #BioPharma
2
73
We are pleased to announce that new data from two IBD studies will be presented at @DDWMeeting. The studies focus on the best-in-class efficacy and safety, novel mechanism and combination therapies of omilancor & TL1A. Read more: nimml.org/news/detail/nimml-…
1
2
79